Episode Details

Back to Episodes

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Episode 802 Published 4 years, 8 months ago
Description

New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields.

In this episode, Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com

A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal life or childhood did not increase risk of JIA. #RheumNow https://t.co/Md0zBm5Txl

Alendronate may protect against type 2 Diabetes. Data from National Danish Patient Registry, presented at the EASD meeting compared 160k T2DM & 500k controls, T2DM following alendronate adjusted OR=0.64; 0.62-0.66; ⋗8yrs OR=0.47 https://t.co/RYEZodUZtv

Analysis of 508 #RA pts (over 10 yrs) in the BeST study shows joint swelling at baseline resulted in half w/ re-swelling later and significantly increased risk of same joint swelling during follow-up (OR 2.37, 95% CI 2.30 to 2.43, p⋖0.001) https://t.co/a7zH4YRAkq

Finnish Pop study 939 #RA pts shows highest healthcare costs linked to high Dz activity & comorbidity. Clusters: C1) young w/ low costs & activity, C2) chronic pain, disability, fatigue, C3) high cost/dz activity, less pain, C4)comorbidities w/ $$$ https://t.co/Azc35zyA9J

A longitudinal study from Iceland shows an increasing number of native joint infections (NJI), with iatrogenic, postarthroscopic infections being of particular concern. Read more… https://t.co/j3gzZ9g0QV

Case controlled study suggests that intraarticular steroid injections is associated with increased (HR 8.56; 3.29-22.3) risk of rapidly destructive hip disease (RDHD); at a rate of 5.4% (5.1 mos post injx) w/ JSN, osteolysis, fem head collapse https://t.co/grX5bO4495<

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us